MRNA vs PAYX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 16, 2026

MRNA

42.8
AI Score
VS
MRNA Wins

PAYX

41.9
AI Score

Investment Advisor Scores

MRNA

43score
Recommendation
HOLD

PAYX

42score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA PAYX Winner
Revenue 534.00M 4.91B PAYX
Net Income -2.13B 1.34B PAYX
Net Margin -397.9% 27.3% PAYX
Operating Income -2.20B 1.91B PAYX
ROE -31.4% 33.4% PAYX
ROA -19.4% 7.6% PAYX
Total Assets 10.96B 17.51B PAYX
Cash 1.72B 1.74B PAYX
Debt/Equity 0.09 1.23 MRNA
Current Ratio 2.29 1.26 MRNA
Free Cash Flow -1.25B 1.81B PAYX

Relative Price Performance (Last 90 Days)

MRNA 1M: +40.0% · 3M: +156.6% PAYX 1M: -13.2% · 3M: -4.4%

Current Technical Phase

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (49.6% over 20 days), RSI 64

RSI (14): 63.6 · Price: $196.48

PAYX

Markdown
Sell / avoid

Price below a falling SMA50 (slope -0.7%), weak momentum, RSI 34

RSI (14): 33.6 · Price: $101.55

Fundamentals Snapshot

Metric MRNA PAYX
Market Cap — —
Forward P/E -41.0 17.2
Trailing P/E — 19.8
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin -0.7% 0.7%
Operating Margin -5.6% 0.4%
EPS -7.36 5.10
Dividend Yield — 0.05%

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.